Fusion Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John F. Valliant
- Full Time Employees
- 101
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 270 Longwood Road South Hamilton ON Canada L8P 0A6
- IPO Date
- Jun 26, 2020
- CIK
- 0001805890
- Website
- fusionpharma.com
- Similar Companies
- Business
- Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines for cancer treatment. The company discovers and develops targeted alpha therapeutics that connect alpha particle-emitting isotopes, such as actinium-225, to targeting molecules including antibodies and small molecules to selectively deliver payloads to tumors while minimizing damage to healthy tissues; its proprietary Fast-Clear linker technology enhances safety by promoting rapid clearance from normal tissues. Core pipeline programs include FPI-2265, a PSMA-targeting radioconjugate in Phase 2 for metastatic castration-resistant prostate cancer; FPI-1434, an IGF-1R-targeted radioimmunoconjugate in Phase 1 for solid tumors; FPI-2059, an NTSR1-targeted small molecule radioconjugate in Phase 1 for solid tumors; and earlier-stage candidates such as FPI-2068 targeting EGFR-cMET under collaboration. Fusion operates a Good Manufacturing Practice-compliant facility in Canada capable of producing up to 100,000 doses annually to support its proprietary and partnered programs, serving healthcare sectors primarily in Canada and the United States with global commercial potential. Founded in 2014 and headquartered in Hamilton, Ontario, Canada, Fusion Pharmaceuticals maintains strategic collaborations with AstraZeneca to jointly develop targeted alpha therapies and combinations with DNA damage response inhibitors and immuno-oncology agents; with Merck to evaluate FPI-1434 alongside KEYTRUDA in IGF-1R-expressing solid tumors; and with BWXT Medical for actinium-225 supply scaling. In March 2024, AstraZeneca announced its acquisition of Fusion for up to $2.4 billion, including $2 billion upfront at $21 per share plus $400 million in contingent value rights tied to regulatory milestones; the deal closed on June 4, 2024, making Fusion a wholly owned subsidiary of AstraZeneca with continued operations in Canada and the US, delisting from Nasdaq, and integration into AstraZeneca's oncology portfolio to advance radioconjugates like FPI-2265 toward Phase 3 trials.
Trump administration backs nuclear fusion — as a company tied to Trump invests in it
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
Acquisition of Fusion Pharmaceuticals Completed
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN
2 More Potential Biotech Buyout Targets
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting